Insmed Incorporated (NASDAQ:INSM) Receives $41.45 Consensus Price Target from Analysts

Shares of Insmed Incorporated (NASDAQ:INSM) have been given an average rating of “Buy” by the ten research firms that are covering the firm, MarketBeat Ratings reports. Ten equities research analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $41.45.

INSM has been the topic of several recent analyst reports. Guggenheim raised their target price on Insmed from $50.00 to $52.00 and gave the stock a “buy” rating in a research note on Tuesday, September 5th. Evercore ISI raised their price target on shares of Insmed from $32.00 to $42.00 and gave the company an “outperform” rating in a report on Thursday, September 7th. Morgan Stanley reiterated an “overweight” rating and set a $41.00 target price on shares of Insmed in a research note on Friday, August 4th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $46.00 price objective on shares of Insmed in a research note on Tuesday, September 19th. Finally, StockNews.com assumed coverage on shares of Insmed in a research note on Thursday, October 5th. They set a “sell” rating on the stock.

Insider Activity

In related news, CEO William Lewis sold 112,000 shares of the business’s stock in a transaction that occurred on Friday, October 27th. The shares were sold at an average price of $24.08, for a total value of $2,696,960.00. Following the completion of the transaction, the chief executive officer now owns 342,648 shares of the company’s stock, valued at $8,250,963.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Assenagon Asset Management S.A. grew its holdings in shares of Insmed by 26.6% during the second quarter. Assenagon Asset Management S.A. now owns 1,782,054 shares of the biopharmaceutical company’s stock worth $37,601,000 after buying an additional 374,715 shares in the last quarter. Peregrine Capital Management LLC boosted its holdings in shares of Insmed by 3.0% in the 1st quarter. Peregrine Capital Management LLC now owns 361,647 shares of the biopharmaceutical company’s stock valued at $6,166,000 after buying an additional 10,678 shares during the period. William Blair Investment Management LLC grew its position in shares of Insmed by 9.3% during the 1st quarter. William Blair Investment Management LLC now owns 3,706,678 shares of the biopharmaceutical company’s stock valued at $63,199,000 after buying an additional 316,513 shares during the last quarter. Long Focus Capital Management LLC grew its holdings in shares of Insmed by 11.3% during the first quarter. Long Focus Capital Management LLC now owns 361,649 shares of the biopharmaceutical company’s stock valued at $6,166,000 after purchasing an additional 36,649 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in shares of Insmed by 434.7% during the 1st quarter. SG Americas Securities LLC now owns 55,152 shares of the biopharmaceutical company’s stock worth $940,000 after purchasing an additional 44,838 shares during the period.

Insmed Stock Performance

Shares of INSM stock opened at $24.90 on Thursday. The business’s fifty day moving average is $25.22 and its 200 day moving average is $22.20. Insmed has a 52-week low of $16.04 and a 52-week high of $27.59. The company has a market capitalization of $3.56 billion, a PE ratio of -4.72 and a beta of 1.40.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.